REPLIMUNE GROUP INC (REPL)
US76029N1063 - Common Stock
Oversold Conditions For Replimune Group (REPL)
Commit To Buy Replimune Group At $5, Earn 10.2% Annualized Using Options
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
RP1 monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent and complete response rate of nearly 22 percent in...
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WOBURN, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development...
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
Philip Astley-Sparke to transition from current role of CEO to Executive Chairman Planned leadership changes position the Company for commercialization ...
Replimune Group GAAP EPS of -$0.77 beats by $0.16 (NASDAQ:REPL)
Replimune Group reported Q3 2024 financial results, beating expectations with a GAAP EPS of -$0.77.
Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
Positive data update in December 2023 for all 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma demonstrating durability...
DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
Transformative surfaceome discovery technology enables a comprehensive map of the cancer cell surface to identify a multitude of novel druggable targets....
Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference
WOBURN, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development...
Commit To Buy Replimune Group At $7.50, Earn 31.3% Annualized Using Options
Oversold Conditions For Replimune Group (REPL)
Why Is Replimune (REPL) Stock Down 48% Today?
Replimune stock is dropping on Tuesday as investors in REPL shares react to a clinical trial missing both of its primary endpoints.
Replimune shares crash as skin cancer candidate fails trial (NASDAQ:REPL)
Replimune shares plummeted after their RP1 candidate failed to meet primary endpoints in a trial for treating a type of skin cancer, causing concerns for...
Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers
RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to...
Noteworthy Tuesday Option Activity: CRS, REPL, HOOD
Notable Monday Option Activity: REPL, HRT, ASC
Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research
RP2 as monotherapy and in combination with nivolumab showed a favorable safety profile and durable responses in nearly 30 percent of patients, all with...
Oversold Conditions For Replimune Group (REPL)
Noteworthy Monday Option Activity: VTNR, DISH, REPL
Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients...
Notable Friday Option Activity: REPL, WDFC, PII
Replimune Group Enters Oversold Territory (REPL)
Notable Monday Option Activity: HZO, REPL, AVAV
Noteworthy Friday Option Activity: MDGL, REPL, PANW
Commit To Buy Replimune Group At $12.50, Earn 51.8% Annualized Using Options
Replimune Group is Now Oversold (REPL)
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WOBURN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development...
Replimune Group appoints CFO (NASDAQ:REPL)
Biotechnology company Replimune Group (REPL) said on Tuesday that Emily Hill has been appointed CFO.
Noteworthy Monday Option Activity: REPL, ENPH, CL